西罗莫司脂化物
基本信息
产品名称：
西罗莫司脂化物
英文名称：
Temsirolimus
国产/进口：
进口
产地/品牌：
美国/TargetMol
型号：
参考报价：
面议
销售商：
总点击数：
20
更新日期：
2025-05-27
产品类别：
性能参数
Product Introduction
Bioactivity
英文名: Temsirolimus
描述: Temsirolimus (CCI-779) 是一种mTOR 抑制剂，IC50值为 1.76 μM。它能激活自噬，可防止心脏功能恶化。
细胞实验: For all experiments, cells were plated in six-well plates in complete growth media for overnight. Various doses of CCI-779 or rapamycin analogs were added alone or with FK506 for indicated periods of time. Total cellular lysates were prepared using NuPAGE-LDS sample buffer. Equal amounts of proteins were subjected to immunoblotting analysis using NuPAGE electrophoresis system. Immunoblots were probed with appropriate primary and secondary antibodies following the manufacturer's instructions and detected using enhanced chemiluminescence. β-Actin immunoblotting and/or reversible Ponceau-S staining of nitrocellulose membranes after the transfer was used to visualize the total protein loading [1].
激酶实验: The Flag-tagged wild-type human mTOR (Flag-mTOR) and Flag-mTOR-SI (S2035I, created by site-directed mutagenesis) DNA constructs were transiently transfected into HEK293 cells. Protein extraction and purification of Flag-mTOR and Flag-mTOR-SI were carried out 48 h later as described previously. In vitro kinase assays of purified Flag-mTOR and Flag-mTOR-SI without or with FKBP12 were done and detected by dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) as described [1].
动物实验: Mice bearing PC-3 tumors were treated with CCI-779 (1, 5, 10, and 20 mg per kg per day), or vehicle solution for 3 or 5 days per week for 3 weeks. Mice bearing DU145 tumors were only treated with CCI-779 (20 mg per kg per day) or vehicle solution for 3 weeks. Mice bearing PC-3 tumors received the following treatments: (a) control, vehicle solution for CCI-779; (b) chemotherapy alone, mitoxantrone 1.5 mg/kg or docetaxel 10 mg/kg was injected i.p. weekly for 3 doses; (c) CCI-779 alone, 5 or 10 mg/kg was injected i.p. daily, three times a week for 3 weeks; (4) chemotherapy followed by CCI-779. The largest and perpendicular diameters of tumors were measured twice weekly, and animals were coded using ear tags so that the observer was unaware of their treatment history. Tumor volume was estimated and plotted against time to evaluate response to treatment [2].
体外活性: Temsirolimus (CCI-779; 10 nmol/L to <5 μmol/L) exhibited a generally flat and cell-selective inhibition of cell proliferation. The most sensitive cell lines that were inhibited by ≥50% included LNCap, PC3MM2, MDA468, H446, and Caco2, whereas those with ≤25% inhibition were SW480, HT29, HCT116, and H460 [1]. Following a 3-day exposure to 100 nmol/L CCI-779, the numbers of colony-forming PC-3 and DU145 cells were 0.18 ± 0.09 and 0.37 ± 0.03, respectively, compared with controls [2].
体内活性: The growth of PC-3 tumors was inhibited by CCI-779 in a dose-dependent manner and growth inhibition was greater than for DU145 tumors. Mean delay in growth to a volume of 500 mm3 was 39 ± 5 and 17 ± 3 days, respectively, following treatment with CCI-779 (20 mg/kg i.p.) five times weekly for 3 weeks. Mice were randomized to treatment with 5 to 10 mg/kg/d of CCI-779 or vehicle alone as a control [2]. Mice were treated 6 days per week. A statistically significant improvement in disease burden was seen in all samples tested. Mice xenografted from 3 of the patients (96, 240, and 359) had a statistically significant decrease in splenic disease bulk [3]. CCI-779, given as 10 intraperitoneal injections, induced significant dose-dependent, antitumor responses against subcutaneous growth of 8226, OPM-2, and U266 cell lines. Effective doses of CCI-779 were associated with modest toxicity, inducing only transient thrombocytopenia and leukopenia. Although CCI-779-mediated inhibition of the p70 mTOR substrate was equal in 8226 and OPM-2 tumor nodules, OPM-2 tumor growth was considerably more sensitive to inhibition of proliferation, angiogenesis, and induction of apoptosis [4].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 70 mg/mL (67.9 mM)
关键字: Inhibitor | Autophagy | NSC-683864 | CCI 779 | Mammalian target of Rapamycin | NSC683864 | Apoptosis | CCI779 | mTOR | Temsirolimus | inhibit
相关产品: 3'-Hydroxypterostilbene | 4-Hydroxybenzyl alcohol | Dasatinib monohydrate | EPI-001 | Calpeptin | Lysophosphatidylcholines | Pemetrexed disodium | Actein | Thapsigargin | Farudodstat
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Neuronal Differentiation Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library
Bioactivity
英文名: Temsirolimus
描述: Temsirolimus (CCI-779) 是一种mTOR 抑制剂，IC50值为 1.76 μM。它能激活自噬，可防止心脏功能恶化。
细胞实验: For all experiments, cells were plated in six-well plates in complete growth media for overnight. Various doses of CCI-779 or rapamycin analogs were added alone or with FK506 for indicated periods of time. Total cellular lysates were prepared using NuPAGE-LDS sample buffer. Equal amounts of proteins were subjected to immunoblotting analysis using NuPAGE electrophoresis system. Immunoblots were probed with appropriate primary and secondary antibodies following the manufacturer's instructions and detected using enhanced chemiluminescence. β-Actin immunoblotting and/or reversible Ponceau-S staining of nitrocellulose membranes after the transfer was used to visualize the total protein loading [1].
激酶实验: The Flag-tagged wild-type human mTOR (Flag-mTOR) and Flag-mTOR-SI (S2035I, created by site-directed mutagenesis) DNA constructs were transiently transfected into HEK293 cells. Protein extraction and purification of Flag-mTOR and Flag-mTOR-SI were carried out 48 h later as described previously. In vitro kinase assays of purified Flag-mTOR and Flag-mTOR-SI without or with FKBP12 were done and detected by dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) as described [1].
动物实验: Mice bearing PC-3 tumors were treated with CCI-779 (1, 5, 10, and 20 mg per kg per day), or vehicle solution for 3 or 5 days per week for 3 weeks. Mice bearing DU145 tumors were only treated with CCI-779 (20 mg per kg per day) or vehicle solution for 3 weeks. Mice bearing PC-3 tumors received the following treatments: (a) control, vehicle solution for CCI-779; (b) chemotherapy alone, mitoxantrone 1.5 mg/kg or docetaxel 10 mg/kg was injected i.p. weekly for 3 doses; (c) CCI-779 alone, 5 or 10 mg/kg was injected i.p. daily, three times a week for 3 weeks; (4) chemotherapy followed by CCI-779. The largest and perpendicular diameters of tumors were measured twice weekly, and animals were coded using ear tags so that the observer was unaware of their treatment history. Tumor volume was estimated and plotted against time to evaluate response to treatment [2].
体外活性: Temsirolimus (CCI-779; 10 nmol/L to <5 μmol/L) exhibited a generally flat and cell-selective inhibition of cell proliferation. The most sensitive cell lines that were inhibited by ≥50% included LNCap, PC3MM2, MDA468, H446, and Caco2, whereas those with ≤25% inhibition were SW480, HT29, HCT116, and H460 [1]. Following a 3-day exposure to 100 nmol/L CCI-779, the numbers of colony-forming PC-3 and DU145 cells were 0.18 ± 0.09 and 0.37 ± 0.03, respectively, compared with controls [2].
体内活性: The growth of PC-3 tumors was inhibited by CCI-779 in a dose-dependent manner and growth inhibition was greater than for DU145 tumors. Mean delay in growth to a volume of 500 mm3 was 39 ± 5 and 17 ± 3 days, respectively, following treatment with CCI-779 (20 mg/kg i.p.) five times weekly for 3 weeks. Mice were randomized to treatment with 5 to 10 mg/kg/d of CCI-779 or vehicle alone as a control [2]. Mice were treated 6 days per week. A statistically significant improvement in disease burden was seen in all samples tested. Mice xenografted from 3 of the patients (96, 240, and 359) had a statistically significant decrease in splenic disease bulk [3]. CCI-779, given as 10 intraperitoneal injections, induced significant dose-dependent, antitumor responses against subcutaneous growth of 8226, OPM-2, and U266 cell lines. Effective doses of CCI-779 were associated with modest toxicity, inducing only transient thrombocytopenia and leukopenia. Although CCI-779-mediated inhibition of the p70 mTOR substrate was equal in 8226 and OPM-2 tumor nodules, OPM-2 tumor growth was considerably more sensitive to inhibition of proliferation, angiogenesis, and induction of apoptosis [4].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 70 mg/mL (67.9 mM)
关键字: Inhibitor | Autophagy | NSC-683864 | CCI 779 | Mammalian target of Rapamycin | NSC683864 | Apoptosis | CCI779 | mTOR | Temsirolimus | inhibit
相关产品: 3'-Hydroxypterostilbene | 4-Hydroxybenzyl alcohol | Dasatinib monohydrate | EPI-001 | Calpeptin | Lysophosphatidylcholines | Pemetrexed disodium | Actein | Thapsigargin | Farudodstat
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Neuronal Differentiation Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library
公司简介
TargetMol（陶术）作为一家全球性的生物医药领域高科技企业，我们致力于为高校、研究所、医院、企业等各类生物医药研发机构提供优质的产品和服务，为全球医药科学家更高效地完成科研工作助力。可提供20,000+种 抑制剂和激动剂 、800+种 化合物库 、19,000+种 天然产物 ，以及9,000+种 重组蛋白 、多种 多肽 、抗体 和 生命科学试剂盒 等。此外，在上海，TargetMol研发中心配备了 CADD & AIDD研究中心、药理实验室和药物化学合成 平台三大技术中心，可提供虚拟筛选、化合物活性测试、分子间结合力检测和化合物结构优化等技术服务，多方位满足用户的研发需求。
售后服务
相关视频
暂无
资料下载
暂无
联系方式
| 单位名称： |
|
详细地址：
静安区江场三路238号
|
|
qq：
2881954871
|
|
联系电话：
021-33632979
|
| Email： |
